- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT04193020
Acute and Chronic Inflammatory Disease, Lifestyle and Treatment Response (ACID LTR)
Impact of Lifestyle and Treatment on the Recurrency and Severity of Acute and Chronic Inflamatory Eye Diseases: Protocol on Prospective Cohort Study
Acute and chronic inflammatory eye diseases are difficult to diagnose and maintain quiescent with therapy. Proposed study is aimed to find on the one hand, novel factors for recurrence of the disease or remission of inflammation and evaluation of the impact of lifestyle and known factors on the other.
Each patient is treated in accordance to the best of medical knowledge and guidelines for each disease.
This prospective cohort study will enroll uveitic patients to the steroid only group (SG), combined (steroid and adjuvant drug) group (CG) or bilogic therapy group (BTG).
At baseline, patient data are recorded using patient-reported outcome measures and clinical assessments (ophthalomology) on disease activity (clinical scales), quality of life, and lifestyle together with registry data on comorbidity and medication. During follow-up evaluation of a successful treatment outcome response will be based on clinical scales and most frequently used primary endpoints; the major outcome of the analyses will be to detect differences in treatment outcome between patients in different treatment group.
Panoramica dello studio
Tipo di studio
Iscrizione (Anticipato)
Contatti e Sedi
Contatto studio
- Nome: Joanna Przeździecka-Dołyk, PhD
- Numero di telefono: +49605693022
- Email: joanna.przezdziecka-dolyk@umed.wroc.pl
Luoghi di studio
-
-
-
Wrocław, Polonia, 54-622
- Reclutamento
- Department of Ophthalmology
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
- Adulto più anziano
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Descrizione
Inclusion Criteria:
- new diagnosis of uni or bilateral uveitis
- recurrence of the diagnosed previously uni or bilateral uveitis
Exclusion Criteria:
- not mentally able to reply the questionnaire
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: Coorte
- Prospettive temporali: Prospettiva
Coorti e interventi
Gruppo / Coorte |
Intervento / Trattamento |
---|---|
steroid only group (SG)
|
Surveillance card and additional examination to find novel markers and better assess the existing ones
|
combined (steroid and adjuvant drug) group (CG)
|
Surveillance card and additional examination to find novel markers and better assess the existing ones
|
bilogic therapy group (BTG)
|
Surveillance card and additional examination to find novel markers and better assess the existing ones
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
Treatment success
Lasso di tempo: 1 year
|
Total number of treatment success in each group
|
1 year
|
Recurrence time
Lasso di tempo: 10 years
|
Time to the next recurrence after the treatment regimen introduction
|
10 years
|
Severe visual loss
Lasso di tempo: 10 years
|
Time and cause of severe visual loss
|
10 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
ETDRS Visual Acuity
Lasso di tempo: 10 years
|
Visual Acuity will be performed with ETDRS charts different for right and left eye
|
10 years
|
The SUN working group grading system for anterior chamber cells
Lasso di tempo: 10 years
|
At each visit anterior chamber will be examined to assess anterior chamber cells (1mm x 1mm slit beam in height and width, when thrown at an angle of 45-60°).
The recorded number of cells will be used to determine the grade according to the SUN criteria.
|
10 years
|
The SUN working group grading system for anterior chamber flare
Lasso di tempo: 10 years
|
At each visit anterior chamber will be examined to assess anterior chamber flare (1mm x 1mm slit beam in height and width, when thrown at an angle of 45-60°).
The observed changes will be used to determine the grade according to the SUN criteria.
|
10 years
|
AREDS 2008 Clinical Lens Opacity Grading Procedure
Lasso di tempo: 10 years
|
Using AREDS system for classifying cataracts from photographs: AREDS Report No. 4 the lens opacity will be graded.
|
10 years
|
NIH grading system for vitreous cells
Lasso di tempo: 10 years
|
At each visit vitreous will be examined to assess vitreous cells (1mm x 3mm slit beam in anterior vitreous).
The recorded number of cells will be used to determine the grade according to the NIH criteria.
|
10 years
|
NIH grading system for vitreous haze
Lasso di tempo: 10 years
|
At each visit vitreous will be examined to assess vitreous haze.
The recorded of clarity of posterior pole funduscopy will be used to determine the grade according to the NIH criteria.
|
10 years
|
Submacular choroidal thickness
Lasso di tempo: 10 years
|
OCT EDI recordings processed with developed by researchers methodology for image processing.
|
10 years
|
Altre misure di risultato
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
---|---|---|
COVID-19 confirmed infection asymptomatic patient
Lasso di tempo: 1 year
|
PCR-positive result of COVID-19 specific testing, no treatment required
|
1 year
|
COVID-19 confirmed infection
Lasso di tempo: 1 year
|
PCR-positive result of COVID-19 specific testing, patient require treatment.
The mode of treatment will be recorded into several groups: 1) antibiotics, 2) antivirals, 3) biologic treatment, 4) immunoglobulins, 5) steroids
|
1 year
|
COVID-19 related acute respiratory distress syndrome (ARDS)
Lasso di tempo: 1 year
|
COVID-19 related acute respiratory distress syndrome (ARDS).
Situation in which patients need any of described below: 1) supportive oxygen therapy, 2) non-invasive ventilation, 3) invasive/ mechanical ventilation, 4) use of ECMO, 5) admission to intensive care unit, 6) dialysis
|
1 year
|
Ocular Surface Disease Index
Lasso di tempo: 1 year
|
Ocular Surface Disease Index (OSDI) questionaire results are used to define if during the course of the disease the dry eye syndrom occurs.
Used with subclasses describing the vision-related functions, ocular symptoms, environmental triggers
|
1 year
|
Dry Eye Questionnaire
Lasso di tempo: 1 year
|
Dry Eye Questionnaire (DEQ 5) questionaire results are used to define if during the course of the disease the dry eye syndrom occurs.
Used with subscales describing the eye dyscomfort, eye dryness and watery eyes.
|
1 year
|
SANDE Questionnaire
Lasso di tempo: 1 year
|
SANDE Questionnaire that assess the frequency and severity of symptoms during the treatment.
|
1 year
|
LIKERT Questionnaire
Lasso di tempo: 1 year
|
LIKER Questionnaire that assess the frequency, severity of symptoms and infuence of symptoms on the patient day-to-day activities during the treatment.
|
1 year
|
LIPCOF scale
Lasso di tempo: 1 year
|
Assesment of conjunctival folds according to pre-defined scale.
|
1 year
|
OXFORD scale
Lasso di tempo: 1 year
|
OXFORD scale conducted with instalation of 2 microliters of 2% fluorescite into the conjunctival sac and assessment according to the pre-defined scale.
The subscales for nasal, temporal and lower lid conjunctiva as well as for cornea was used.
The scale has been conducted during the treatment period and if necessary during additional visits.
|
1 year
|
SICCA scale
Lasso di tempo: 1 year
|
SICCA scale conducted with instalation of 2 microliters of 2% fluorescite into the conjunctival sac and assessment of cornea according to the pre-defined scale.
Different dye was used for conjunctica (lizamine green).
The subscales for nasal and temporal conjunctiva as well as for cornea was used.
The scale has been conducted during the treatment period and if necessary during additional visits.
|
1 year
|
Collaboratori e investigatori
Sponsor
Collaboratori
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Anticipato)
Completamento dello studio (Anticipato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ST-859
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Surveillance card
-
Radboud University Medical CenterJeroen Bosch ZiekenhuisSconosciutoComunicazione | Partecipazione del pazienteOlanda
-
King George's Medical UniversityIndian Council of Medical ResearchCompletatoMorbilità neonatale | Malattie neonataliIndia
-
Mayo ClinicTerminatoReflusso gastroesofageo | Ernia, iatale | Sondaggi e questionari | FundoplicatioStati Uniti
-
VA Office of Research and DevelopmentCompletatoFattibilità | Rischio di suicidio | Accettabilità | Connessione sociale | Appartenenza contrastata | Gravità percepitaStati Uniti
-
University College, LondonCompletatoTumori maligni CD19+: recidiva post-trapianto allogenicoRegno Unito
-
Medical University InnsbruckBarmherzige Brüder Vienna; Tiroler Landeskrankenanstalten GmbH (TILAK); Tiroler... e altri collaboratoriCompletatoIctus | Attacco ischemico, transitorio | Analisi costi benefici | Prevenzione secondaria | Gestione delle malattieAustria
-
University of TorontoPublic Health Agency of Canada (PHAC); Wholehealth Pharmacy PartnersNon ancora reclutamentoReazione alla vaccinazione | Dolore da vaccinazione | Farmacia ComunaleCanada
-
Ottawa Hospital Research InstituteThe Hospital for Sick Children; University of Ottawa; Children's Hospital of Eastern... e altri collaboratoriSconosciutoSimulazione | Infarto | Rianimazione cardiopolmonare | Formazione scolasticaCanada
-
University of PennsylvaniaCompletatoChirurgia | Uso di oppioidi | Abuso di oppioidi | Abuso di oppioidi da prescrizioneStati Uniti